Design and evaluation of a pegylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier

AAPS Journal

Volumn 16, Issue 1, 2014, Pages 114-124

  Zhang, Peng ^a,b   Lu, Jianqin ^a,b   Huang, Yixian ^a,b   Zhao, Wenchen ^a   Zhang, Yifei ^a,b   Zhang, Xiaolan ^a,b   Li, Jiang ^a,b   Venkataramanan, Raman ^a   Gao, Xiang ^a,b   Li, Song ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Drug interactive motif; Micelle; Paclitaxel; Slow release

Indexed keywords

ANTIOXIDANT; CYCLOSPORIN A; DRUG CARRIER; JP 4039; LIPOPEPTIDE; NICLOSAMIDE; PACLITAXEL; POLYETHYLENE GLYCOL 5000 LYSINE(ALPHA 9 FLUORENYLMETHOXYCARBONYL EPSILON OLEOYL LYSINE) 2; PROBUCOL; PROGESTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CHEMICAL ANALYSIS; CRITICAL MICELLE CONCENTRATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PHOTOCHEMICAL QUENCHING; PHYSICAL CHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; MICELLES; PACLITAXEL; PHARMACOKINETICS; POLYETHYLENE GLYCOLS;

EID: 84893700710     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9536-9     Document Type: Article

References (44)

1. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59:603-16.
2. Löbenberg R, Amidon GL, Vierira M. Solubility as a limiting factor to drug absorption. In: Dressman JB, Lennernäs H, editors. Oral Drug Absorption: Prediction and Assessment. New York: Marcel Dekker; 2000. p. 137.
3. Matsumura Y. Poly(amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev. 2008;60:899-914.
4. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-84.
5. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189-207.
6. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9:253-66.
7. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005;109:169-88.
8. Kim JY, Kim S, Papp M, Park K, Pinal R. Hydrotropic solubilization of poorly water-soluble drugs. J Phar Sci. 2010;99:3953-65.
9. Kim JY, Kim S, Pinal R, Park K. Hydrotropic polymer micelles as versatile vehicles for delivery of poorly water-soluble drugs. J Control Release. 2011;152:13-20.
10. Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release. 2004;100:247-56.
11. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 2004;96: 273-83.
12. Mi Y, Liu Y, Feng SS. Formulation of Docetaxel by folic acidconjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS2k) micelles for targeted and synergistic chemotherapy. Biomaterials. 2011;32:4058-66.
13. Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012;33:4889-906.
14. Lu J, Huang Y, Zhao W, Marquez RT, Meng X, Li J, et al. PEGderivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. Biomaterials. 2013;34:1591-600.
15. Huang Y, Lu J, Gao X, Li J, Zhao W, Sun M, et al. PEGderivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug Chem. 2012;23:1443-51.
16. Zhang X, Lu J, Huang Y, Zhao W, Chen Y, Li J, et al. PEG- farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel. Bioconjug Chem. 2013;24:464-72.
17. Gao X, Huang Y, Makhov AM, Epperly M, Lu J, Grab S, et al. Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers. Mol Pharm. 2013;10: 187-98.
18. Kang N, Leroux JC. Triblock and star-block copolymer of N-(2-hydroxypropyl)methacrylamide or N-vinyl-2-pyrrolidone and d, llactide: synthesis and self-assembling properties in water. Polymer. 2004;45:8967-80.
19. Lavasanifar A, Samuel J, Kwon GS. The effect of alkyl core structure on micellar properties of poly(ethylene oxide)-blockpoly(l-aspartamide) derivatives. Colloids Surf B Biointerfaces. 2001;22:115-26.
20. Kwon GS, Natio M, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Micelles based on AB block copolymers of poly(ethylene oxide) and poly(β benzyl l-aspartate). Langmuir. 1993;9:945-9.
21. Shirai K, Matsuoka M, Fukunishi K. Fluorescence quenching by intermolecular π-π interactions of 2,5-bis(N, N-dialkylamino)- 3,6-dicyanopyrazines. Dyes Pigm. 1999;42:95-101.
22. Zhou M, Smith AM, Das AK, Hodson NW, Collins RF, Ulijn RV, et al. Self-assembled peptide-based hydrogels as scaffolds for anchorage-dependent cells. Biomaterials. 2009;30:2523-30.
23. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2007;2:249-55.
24. Goldspiel BR. Clinical overview of the taxanes. Pharmacotherapy. 1997;17:110S-25S.
25. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82:1247-59.
26. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 1994;48:794-847.
27. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995;95:1869-76.
28. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590-8.
29. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263-8.
30. Kloover JS, den Bakker MA, Gelderblom M, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer. 2004;90:304-5.
31. Gao Z, Lukyanov AN, Singhal A, Torchilin VP. Diacyl-polymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Lett. 2002;2:979-82.
32. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56:1273-89.
33. Gao Z, Lukyanov AN, Chakilam AR, Torchilin VP. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J Drug Target. 2003;11:87-92.
34. Jack DB. Handbook of clinical pharmacokinetics data. Houndmills, UK: MacMillan Publisher's Ltd; 1992.
35. Persson EM, Gustafsson AS, Carlsson AS, Nilsson RG, Knutson L, Forsell P, et al. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res. 2005;22:2141-51.
36. Nendza M, Müller M. Discriminating toxicant classes by mode of action: 3. Substructure indicators. SAR QSAR Environ Res. 2007;18:155-68.
37. Yang W, de Villiers MM. Effect of 4-sulphonato-calix[n]arenes and cyclodextrins on the solubilization of niclosamide, a poorly water soluble anthelmintic. AAPS J. 2005;7:E241-8.
38. Alvarez Núñez FA, Yalkowsky SH. Correlation between log P and Clog P for some steroids. J Pharm Sci. 1997;86:1187-9.
39. Nandi I, Bateson M, Bari M, Joshi HN. Synergistic effect of PEG-400 and cyclodextrin to enhance solubility of progesterone. AAPS Pharm Sci Tech. 2003;4:1-5.
40. Yang ZQ, Xu J, Pan P, Zhang XN. Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats. Pharmazie. 2009;64:26-31.
41. 2+. Eur J Pharmacol. 1999;366:309-17.
42. Yang W, de Villiers MM. The solubilization of the poorly water soluble drug nifedipine by water soluble 4-sulphonic calix[n]arenes. Eur J Pharm Biopharm. 2004;58:629-36.
43. Mithani SD, Bakatselou V, Ten Hoor CN, Dressman JB. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res. 1996;13:163-7.
44. Gramatté T. Griseofulvin absorption from different sites in the human small intestine. Biopharm Drug Dispos. 1994;15: 747-59.